[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-diagnosis":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,43,75,104,144,178,203,226,253,274,302,329,352,381,407,435,468,490,518,546,574,594,623,651,673],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100597536","phase-2-phase-iia-trial-in-participants-with-asthma-to-evaluate-impact-of-intranasal-eth47-on-development-of-asthma-related-symptoms-following-rhinovirus-challenge-100597536",false,"NCT07059767","Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge","A Phase IIa, Double-blind, Randomized, Placebo-controlled Trial in Participants With Asthma to Evaluate the Impact of Intranasal ETH47 on the Development of Asthma-related Symptoms Following Rhinovirus Challenge","ETH47-201","Inclusion Criteria:\n\n1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n2. Participants aged ≥18 and ≤65 years at the time of obtaining informed consent.\n3. Diagnosis of clinical asthma (\\>12% reversibility following short acting beta 2 agonist (SABA) treatment or PC20 methacholine challenge of \\\u003C8 mg\u002FmL).\n4. Stable (no change in medication or dose) asthma maintenance therapy with inhaled glucocorticosteroids (ICS) or ICS + long acting beta 2 agonist (LABA) for at least 3 months prior to dosing.\n5. Clinically stable with no exacerbations within 3 months prior to dosing.\n6. Sero-negative test result to RV-A16.\n7. Participants must agree to use contraception methods (if applicable).\n\nExclusion Criteria:\n\n1. Any cold symptom within the last month such as sore throat, sneezing, rhinorrhoea, malaise, nasal obstruction or cough.\n2. Evidence of current allergic rhinitis, including perennial allergic rhinitis, or rhinosinusitis or nasal polyps.\n3. History of or current diagnosis of chronic obstructive pulmonary disease, emphysema, cystic fibrosis or bronchiectasis.\n4. The evidence of any other historic, active or chronic disease following a detailed medical and surgical history which, in the Investigator's judgement, puts the participant at risk due to participation in the trial, may influence the results of the trial, or the participant's ability to participate in the trial. This includes a history of emergency room visits or hospital admissions due to common cold.\n5. Current vaper or smoker, or ex-smoker who stopped within the last 12 months or with a \\>5 year pack history; current vapers may be included if willing to stop prior to Baseline.","ALL","18 Years","65 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge",[29],"Asthma (Diagnosis)","RECRUITING","2026-06-25",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2025-06-24",{"date":38,"type":23},"2026-06",{"name":40,"class":41},"Ethris GmbH","INDUSTRY",2,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100644974","phase-2-a-long-term-study-of-kt-621-administered-orally-to-participants-with-asthma-previously-enrolled-in-a-kt-621-asthma-study-100644974","NCT07677059","A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study","A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study","BREADTH-EXT","Inclusion Criteria:\n\n* Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit.\n* Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.\n* Must agree to contraceptive requirements in compliance with the clinical study and local requirements.\n\nExclusion Criteria:\n\n* Must not have experienced any clinically significant change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study.\n* Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant.\n* Must not have met permanent discontinuation criteria and\u002For permanently discontinued study treatment for any reason during the parent study.\n* Must not be a member of the Sponsor or site's investigational team or their immediate family.\n* Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures.",{"count":52,"type":23},264,[26],"This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.",[29],[57,58,59,60,61,62,63,64],"KT-621","STAT6","stat6 degrader","targeted protein degrader","Phase 2","phase 2b","OLE","LTE","2026-06-24",{"date":67,"type":34},"2026-06-30",{"date":69,"type":23},"2026-07",{"date":71,"type":23},"2028-12",{"name":73,"class":41},"Kymera Therapeutics, Inc.",1,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":42},"100642439","phase-4-evaluation-of-allergen-specific-vaccination-of-dog-allergic-patients-in-swedish-practice-100642439","NCT07651891","Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice","ALLERDOG","Inclusion Criteria\n\nThe subject has provided written informed consent to participate in the study.\n\n* Age 18-50 years.\n* Moderate-to-severe allergic symptoms upon exposure to dogs.\n* Dog allergy confirmed by positive specific IgE.\n* Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC).\n* Female subjects of childbearing potential must use adequate contraception.\n* A negative pregnancy test must be obtained prior to enrolment.\n\nExclusion Criteria\n\n* Pregnancy or breastfeeding.\n* Autoimmune or connective tissue disease.\n* Cardiovascular disease.\n* Hepatic disease.\n* Renal disease.\n* Malignancy.\n* Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis).\n* Chronic obstructive or restrictive lung disease.\n* Treatment with medications that may interfere with the immune response.\n* Previous immunotherapy or chemotherapy.\n* Significant chronic disease.\n* Major metabolic disease.\n* Alcohol or substance abuse.\n* Mental or cognitive incapacity that may impair compliance with study procedures.\n* Known or suspected hypersensitivity to the study product.\n* Suspected or confirmed bacterial infection.\n* Clinically relevant allergy to house dust mite.\n* Current dog ownership.\n* Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate.\n* Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.","50 Years",{"count":84,"type":23},40,[86],"PHASE4","STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls.\n\nSTUDY OUTLINE\n\nThe study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected.\n\nFollowing the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline.\n\nAllergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.",[89,29],"Allergic Rhinitis",[91,92,93,94],"AIT","SCIT","Allergic rhinitis","Asthma",{"date":96,"type":34},"2026-06-29",{"date":98,"type":23},"2026-08-01",{"date":100,"type":23},"2027-12-01",{"name":102,"class":103},"Karolinska Institutet","OTHER",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":24,"phases":115,"briefSummary":117,"conditions":118,"keywords":124,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":74},"100642489","dash-obesity-explainable-ai-for-family-centric-personalized-weight-control-in-adolescents-and-young-adults-with-obesity-and-chronic-conditions-100642489","NCT07638345","DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions","US-based Clinical Sub-study of DASH-Obesity: Explainable AI for Family-Centric Transdiagnostic Personalized Weight Control Across Multiple Conditions","DASH-Obesity","Inclusion Criteria:\n\n* Adult caregiver (aged 18 years or older) of an adolescent or young adult aged 12 to 21 years diagnosed with Type 1 Diabetes (T1D) or asthma.\n* The caregiver is actively involved in the management of the adolescent's or young adult's condition.\n* The adolescent or young adult must meet one of the following criteria:\n* T1D and normal weight (BMI between the 10th and 85th percentile), or\n* T1D and overweight\u002Fobesity (BMI ≥85th percentile), or\n* Asthma and overweight\u002Fobesity (BMI ≥85th percentile).\n* Willingness to participate in the Adhera Caring Digital Program-Obesity (ACDP-O).\n* Access to a smartphone or internet-enabled device compatible with the study application.\n* Willingness to provide self-reported information regarding the adolescent's or young adult's health status, including disease-related and anthropometric measures.\n* For caregivers of participants with T1D, willingness to share continuous glucose monitoring (CGM) information.\n\nExclusion Criteria:\n\n* Severe psychiatric or cognitive conditions that would interfere with participation in the digital intervention.\n* Current participation in another obesity- or chronic disease-related digital health intervention study.\n* Inability or unwillingness to comply with study procedures.\n* Refusal or inability to provide informed consent.",true,{"count":114,"type":23},280,[116],"NA","This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with overweight\u002Fobesity and chronic conditions, including type 1 diabetes (T1D) and asthma. The intervention combines personalized educational content, wearable-device monitoring, psychometric assessments, and explainable artificial intelligence (AI) to improve mental well-being, quality of life, and adherence to healthy lifestyle behaviors. A total of 280 families will participate in a 3-month intervention with remote monitoring and follow-up assessments.",[119,120,121,122,123,29],"Type 1 Diabetes","T1D","Obesity & Overweight","Obesity Type 2 Diabetes Mellitus","Asthma Acute",[125,119,94,126,127,128,129,130,131,132,133,134],"Pediatric Obesity","Overweight","Digital Health","Artificial Intelligence","Explainable AI","Caregiver Burden","Quality of Life","Mental Well-being","Wearable Devices","Family-Centered Care","2026-06-19",{"date":137,"type":34},"2026-06-23",{"date":139,"type":34},"2025-10-30",{"date":141,"type":23},"2026-09",{"name":143,"class":41},"Adhera Health, Inc.",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":112,"sex":18,"minAge":19,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":156,"conditions":157,"keywords":162,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":74},"100642831","breathlessness-perceptions-within-respiratory-diseases-100642831","NCT07648082","Breathlessness Perceptions Within Respiratory Diseases","Exploring Differences in Breathlessness Perceptions Within Respiratory Diseases","BiRD","Inclusion Criteria:\n\n* • Aged 18 or over up to 100\n\n  * Known respiratory diagnosis\\* OR Healthy control\\*\\*\n  * Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale\n  * Able to communicate in English\n  * Able to attend two study visits\n  * Able to provide written informed consent\n\n    * Known respiratory diagnosis could include, but is not limited to, COPD, Asthma, Bronchiectasis or ILD.\n    * Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal.\n\nExclusion Criteria:\n\n* • Unstable disease or undergoing investigations for unexplained symptoms\n\n  * Undergone a surgery within past six weeks\n  * Contraindications for exercise outlined by ACSM guidelines (Unstable CVD, hypertension etc)\n  * BMI ≥ 35kg\u002Fm2\n  * Unable to communicate in English\n  * Unable to provide written informed consent\n  * Unable to abstain from smoking for 8 hours prior to testing","100 Years",{"count":154,"type":23},75,"OBSERVATIONAL","Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological, psychological and functional factors but these are poorly explored. There are also unexplored phenomenon's such as breathing pattern. Therefore, this study aims to understand the influences of physiology, psychology, function and breathing pattern on health related quality of life in those with a respiratory disease compared to healthy controls. This project is a cross-sectional cohort study including those with a known respiratory disease and experiencing breathlessness, compared to non-breathless healthy controls. The investigators will measure your physiology through spirometry (a breathing test that tells us about their lung function), psychology through questionnaires, function through an exercise test and breathing pattern using opto-electrictronic plethysmography (markers are placed on your chest to see how participants breathe while exercising). This will be conducted over two visits. The investigators will recruit participants from clinics at the University Hospitals of Leicester NHS Trust. The investigators are aiming to recruit 50 participants with a respiratory disease and 25 healthy controls. The results of this study will help us understand breathlessness in more detail in order to be able to develop better treatments.",[158,29,159,160,161],"Chronic Obstructive Pulmonary Disease (COPD)","Interstitial Lung Disease (ILD)","Bronchiectasis","Breathing Pattern Disorder",[163,164,165,166,167,168],"Breathlessness","OEP","Cardiopulmonary Exercise Testing","Respiratory diseases","Heart rate variability","Breathing patterns","2026-06-10",{"date":171,"type":34},"2026-06-15",{"date":173,"type":34},"2025-06-06",{"date":175,"type":23},"2026-07-01",{"name":177,"class":103},"University Hospitals, Leicester",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":112,"sex":18,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":187,"studyType":155,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100643772","a-study-to-evaluate-the-diagnostic-performance-of-portable-oscillometry-across-chronic-respiratory-diseases-100643772","NCT07631507","A Study to Evaluate the Diagnostic Performance of Portable Oscillometry Across Chronic Respiratory Diseases","Inclusion Criteria:\n\n* COPD group:\n\n  * Age：≥40\n  * Suspected COPD：COPD-SQ≥16，and no evidence of airflow limitation after bronchodilators\n  * Confirmed COPD：According to the diagnostic criteria in the 2021 Revised Edition of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease and the 2026 GOLD Report, a diagnosis requires the presence of symptoms (such as dyspnea, chronic cough, or sputum production), a history of exposure to risk factors (e.g., smoking, biomass fuels, occupational exposures, or air pollution), evidence of persistent airflow limitation (post-bronchodilator FEV1\u002FFVC \\\u003C 0.70), and the exclusion of alternative diagnoses.\n  * Exclude acute exacerbation within the last month Asthma group：\n  * Age：≥3\n  * Suspected asthma：Patients with chronic respiratory symptoms but no evidence of variable airflow limitation\n  * Confirmed asthma：According to the diagnostic criteria in the 2024 Chinese Guidelines for the Prevention and Treatment of Bronchial Asthma and the 2025 GINA Report, diagnosis requires the presence of recurrent symptoms (such as wheezing, shortness of breath, chest tightness, and cough) that resolve spontaneously or with treatment; evidence of variable airflow limitation (e.g., a positive bronchodilator reversibility test, a positive bronchial provocation test, or an average daily diurnal PEF variability of \\>10% over at least 7 consecutive days); and the exclusion of alternative diagnoses.\n\nHealthy subjects:\n\n* Age ≥ 3 (See Table 1 for details)\n* No respiratory symptoms（cough, expectoration, shortness of breath, wheezing, etc）\n* No history of serious cardiopulmonary or other systemic diseases, especially no history of respiratory diseases and surgery\n* No history of respiratory infection within the past 4 weeks; non-smoker or total lifetime smoking \\\u003C 100 cigarettes\n* No history of occupational exposure to harmful gases or dust, or serious pollution of the work or living environment\n* No abnormalities on chest physical examination\n* No abnormalities were found on chest imaging (X-ray, CT) records within the past year.\n* Body mass index within the normal range (18.5\\~24.9) Confirmed Bronchiectasis Group：\n* Age ≥ 3 years\n* Clinical history consistent with bronchiectasis, confirmed by CT scan\n* No other concurrent or accompanying respiratory diseases at present Confirmed ILD Group：\n* Age ≥ 3 years\n* Fibrotic interstitial lung disease: HRCT scan shows fibrotic lung disease, defined as reticular abnormalities and traction bronchiectasis with or without honeycombing, and the disease extent \\> 10%; or lung tissue biopsy indicates fibrotic interstitial changes\n* No other concurrent or accompanying respiratory diseases at present Confirmed Upper Airway Obstruction Group：\n* Age ≥ 3 years, gender not restricted\n* History of upper airway inflammation, injury, endotracheal intubation or tracheotomy, burns, foreign body aspiration, tracheal tumor, or other conditions that can cause large airway obstruction\n* Clinical manifestations are mainly dyspnea and shortness of breath, which are significantly aggravated after activity, and sometimes symptom exacerbation is related to body position\n* Pulmonary function test shows significant limitation of inspiratory or expiratory flow in the F-V curve, presenting a characteristic plateau pattern\n* At least one of the following evidences: chest CT scan or upper airway three-dimensional reconstruction confirms upper airway stenosis; laryngoscopy or bronchoscopy reveals tracheal\u002Fbronchial wall thickening and\u002For stenosis, intratracheal nodules or neoplasms, tumor infiltration, tracheal mucosal congestion, tracheal cartilage collapse, etc\n\nExclusion Criteria:\n\n* • Contraindications for oscillometry testing and spirometry testing: Oscillometry testing: Severe and intolerable dyspnea, acute exacerbation of respiratory infection, uncontrolled epilepsy, oral or facial diseases or deformities preventing proper latching, tympanic membrane perforation, need for continuous oxygen therapy, indwelling gastric tube, tracheotomy with inability to close the tube, currently undergoing artificial ventilation and unable to temporarily stop the procedure; Spirometry testing: Recent severe cardiovascular disease, epileptic seizures, uncontrolled hypertension, aortic aneurysm, severe hyperthyroidism, heart rate \\>120 bpm, tympanic membrane perforation, other respiratory infectious diseases, etc.;\n\n  * Other respiratory diseases that affect lung function results： such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, etc.; Recent surgical history that affects lung function results, including open-chest surgery, pleural effusion surgery, etc.;\n  * Poor cooperation during basic lung function tests, failing to meet quality control requirements;\n  * Breastfeeding women;\n  * Participants deemed unlikely by the researcher to comply with research procedures and restrictions.","3 Years",{"count":186,"type":23},4000,"1 Day","This is a prospective, multicenter, observational cohort study enrolling approximately 4,000 subjects across about 50 centers, including patients with COPD (confirmed and suspected), asthma (confirmed and suspected), bronchiectasis, interstitial lung disease (ILD), upper airway obstruction (UAO), and healthy controls. Participants will undergo standardized clinical assessments, cough search, FENO, ETCO2, impulse oscillometry, spirometry, and\u002For bronchodilator test, and\u002For bronchoprovocation test, and\u002For diffusion capacity test at a single baseline visit, with no investigational intervention or treatment assignment. The primary objective is to evaluate the diagnostic performance of portable impulse oscillometry in Chronic respiratory diseases and to develop an artificial intelligence diagnostic model for COPD based on oscillometry. The study duration per subject is limited to the screening\u002Fbaseline visit, with no follow-up visits planned.",[190,29,191,160,159,192],"COPD","Chronic Respiratory Diseases","Upper Airway Obstruction","NOT_YET_RECRUITING","2026-06-02",{"date":196,"type":34},"2026-06-08",{"date":198,"type":23},"2026-07-30",{"date":200,"type":23},"2027-08-30",{"name":202,"class":103},"The First Affiliated Hospital of Guangzhou Medical University",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":24,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100639258","a-study-of-acupuncture-for-treating-asthma-100639258","NCT07611955","A Study of Acupuncture for Treating Asthma","The Effects of Acupuncture on Patients With Chronic Asthma: a Multicenter, Randomized, Three-arm, Sham-controlled Superiority Trial","Inclusion Criteria:\n\n* Meet the diagnostic criteria for asthma, and be in the chronic persistent phase with mild to moderate disease severity, referring to the grading criteria of the Guidelines for the Prevention and Treatment of Asthma (2024 Edition).\n* Aged 18 to 70 years, regardless of gender.\n* Asthma Control Test (ACT) score≤19 points (poorly controlled or very poorly controlled asthma).\n* Maintain a stable asthma treatment regimen for at least 4 weeks before enrollment.\n* Clear thinking and consciousness, coherent responses, able to understand the items of various scales and complete the assessment.\n* Volunteer to participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Complicated with severe mental illnesses (such as uncontrolled schizophrenia, acute phase of bipolar disorder, etc.) or moderate to severe cognitive impairment (such as dementia), resulting in inability to understand the research process or cooperate with efficacy evaluation.\n* A history of substance\u002Falcohol dependence within the past 12 months.\n* Complicated with other physical diseases that may cause depressive symptoms (such as hypothyroidism, chronic pain syndrome, malignant tumors, rheumatoid arthritis, etc.).\n* Received antidepressant drug treatment within the past 6 months.\n* Suffering from other respiratory diseases, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, etc.\n* Complicated with other cancers or relatively severe chronic diseases of the heart, liver, kidneys, etc.\n* Received acupuncture treatment within the past 3 months.\n* Pregnant or lactating women.","70 Years",{"count":212,"type":23},180,[116],"Asthma is a common chronic respiratory disease with a low clinical control rate, highlighting the need for novel therapeutic strategies. Recurrent asthma attacks emotional symptoms, such as anxiety and depression, etc. On the contrary, symptoms such as anxiety and depression worsen asthma control. Acupuncture is commonly applied as an effective traditional Chinese medical therapy for asthma. Acupoints GV14, BL13 and BL12 are adopted for the intervention of asthma. GV20 and GV29 are selected to improve emotional symptoms including depression. Nevertheless, standardized therapeutic regimens of acupuncture for asthma and its concomitant emotional symptoms are still lacking. 180 patients with mild to moderate asthma will be recruited in this multicenter randomized controlled trial, randomly assigned to the true acupuncture group, sham acupuncture group and usual care group. The primary outcome is the score of the Asthma Control Test (ACT). Secondary outcomes include the Hospital Anxiety and Depression Scale (HADS), Asthma Quality of Life Questionnaire (AQLQ), pulmonary function, and fractional exhaled nitric oxide (FeNO). The superiority of combined acupuncture therapy in improving asthma control, relieving negative emotions, and enhancing quality of life is to be verified in this study, with high quality evidence for acupuncture treatment of asthma thereby to be provided.",[216,29,94],"Asthma Chronic","2026-05-28",{"date":219,"type":34},"2026-06-01",{"date":221,"type":23},"2026-05-21",{"date":223,"type":23},"2028-09",{"name":225,"class":103},"Shanghai University of Traditional Chinese Medicine",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":18,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":24,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":249,"leadSponsor":251,"locationsCount":74},"100639872","chronic-effects-of-photobiomodulation-with-an-led-vest-on-functional-capacity-inflammatory-markers-and-muscle-perfusion-in-children-with-asthma-100639872","NCT07613671","Chronic Effects of Photobiomodulation With an LED Vest on Functional Capacity, Inflammatory Markers, and Muscle Perfusion in Children With Asthma","Asthma PBM","Critérios de Inclusão: Crianças em idade escolar de 6 a 17 anos Diagnosticado com asma leve a moderada (tratamento farmacológico regular) clinicamente estável Critérios de exclusão:Histórico de exacerbação da asma dentro de 30 dias antes do início do estudo, FAlha no preenchimento dos questionários","6 Years","17 Years",{"count":236,"type":23},60,[116],"Asthma is a chronic inflammatory disease of the airways that results in tissue remodeling, airflow limitation, and bronchial hyperresponsiveness. This study aims to evaluate the long-term effects of photobiomodulation using an LED vest in the management of pediatric asthma. It is a randomized clinical trial involving children aged 6 to 17 years diagnosed with mild to moderate asthma, divided into two groups: an intervention group (using a vest with active LEDs) and a control group (using the vest turned off, simulating the intervention without light emission). The methodology includes clinical and functional assessments such as spirometry, the Asthma Control Test (ACT), the GINA questionnaire, and the Incremental Step Test (IST), which measures exercise tolerance. Photobiomodulation through LEDs promotes cellular biostimulation without thermal effects, modulating inflammatory processes and optimizing tissue regeneration. It is expected that the LED vest will contribute to improving pulmonary function, enhancing quality of life, and complementing conventional treatments. This project aims to advance the clinical application of photobiomodulation as an accessible and effective therapeutic alternative for pediatric asthma.",[29],[241,242,243,244,245,246],"pediatric asthma","Photobiomodulation Therapy","Pulmonary Function","Inflammatory Biomarkers","Low-Level Light Therapy (LLLT)","asthma",{"date":194,"type":34},{"date":198,"type":23},{"date":250,"type":23},"2028-01-30",{"name":252,"class":103},"University of Nove de Julho",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":112,"sex":18,"minAge":260,"maxAge":19,"enrollmentInfo":261,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":270,"leadSponsor":272,"locationsCount":74},"100638770","multimodal-assisted-diagnosis-for-pediatric-respiratory-diseases-using-questionnaires-cough-sounds-and-breath-sounds-100638770","NCT07613242","Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Questionnaires, Cough Sounds, and Breath Sounds","A Prospective Observational Study of Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Symptom Questionnaires, Cough Sounds, and Breath Sounds","Inclusion Criteria:\n\nChildren aged 28 days to 18 years, regardless of sex, will be eligible for inclusion. The disease group will include children presenting to the outpatient department, emergency department, or inpatient wards of Shanghai Children's Medical Center with cough, wheezing, fever with respiratory symptoms, nasal congestion, rhinorrhea, sore throat, or other respiratory complaints. Participants should be able to complete the symptom questionnaire, cough sound recording, and breath sound recording, and their guardians must provide informed consent and allow review of relevant medical history and diagnostic information. The healthy control group will include children recruited from routine health examinations or children without respiratory complaints, with no acute respiratory symptoms within the past 4 weeks, no known history of chronic respiratory diseases, no obvious respiratory abnormalities on health assessment or research team review, the ability to complete relevant data collection, and guardian informed consent.\n\nExclusion Criteria:\n\nParticipants will be excluded if they have severe cardiopulmonary malformations, long-term tracheostomy or mechanical ventilation, severe neuromuscular disorders, severe immunodeficiency, or other conditions that may substantially alter cough sound characteristics or affect the clinical presentation of respiratory diseases. Children whose primary diagnosis at the current visit is a non-respiratory disease and who are not suitable for this study will also be excluded. Participants who are unable to complete the symptom questionnaire, or whose cough sound or breath sound recordings remain of insufficient quality after repeated attempts, will not be included or will be excluded from the corresponding modality-specific analysis. Participants with only one unavailable modality may be included in analyses based on the completed modalities but will be excluded from analyses requiring the missing modality. Healthy controls will be excluded from the main control analysis if recent respiratory symptoms, a history of chronic respiratory disease, or other conditions that may affect acoustic features are identified.","28 Days",{"count":262,"type":23},1400,"This study aims to establish a standardized, synchronized data collection system for pediatric symptom questionnaires, cough sounds, and breath sounds, and to construct a multimodal database of pediatric respiratory diseases including both disease cases and healthy controls. Using the final research labels determined by clinicians' diagnoses, health status assessments, and research team review as the reference standard, this study will develop and validate a multimodal assisted diagnostic model for common pediatric respiratory diseases based on symptom questionnaires, cough sounds, and breath sounds. The study will primarily evaluate the diagnostic performance of the model in distinguishing healthy children from children with respiratory diseases, screening for asthma and asthma-related cough, and identifying pneumonia, tracheitis\u002Fbronchitis, upper airway-related diseases, and common causes of chronic cough. It will also assess the incremental value of cough sounds and breath sounds beyond symptom questionnaire information.",[29,265],"Community-Acquired Pneumonia (CAP)","2026-05-23",{"date":268,"type":34},"2026-05-29",{"date":219,"type":23},{"date":271,"type":23},"2029-05-31",{"name":273,"class":103},"Shanghai Children's Medical Center",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":18,"minAge":282,"maxAge":234,"enrollmentInfo":283,"targetDuration":4,"studyType":24,"phases":285,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":74},"100638953","vr-vs-treadmill-exercise-in-children-with-asthma-100638953","NCT07610447","VR vs Treadmill Exercise in Children With Asthma","Comparison of Treadmill and Virtual Reality-Based Aerobic Exercise Programs in Children With Asthma","VR-ASTHMA","Inclusion Criteria:\n\n* Children and adolescents aged between 10 and 17 years\n* Physician-diagnosed asthma according to Global Initiative for Asthma (GINA) criteria\n* Stable medical treatment for asthma\n* Ability to participate in an aerobic exercise program\n* Willingness of the participant and parent\u002Flegal guardian to provide informed consent\n\nExclusion Criteria:\n\n* Presence of orthopedic, neurological, cardiovascular, or systemic conditions limiting participation in exercise\n* Contraindications to virtual reality use (e.g., epilepsy, photosensitivity)\n* Participation in a structured exercise program within the previous month\n* Asthma exacerbation within the previous month\n* Obesity diagnosis","10 Years",{"count":284,"type":23},30,[116],"This study aims to compare the effects of virtual reality-based aerobic exercise and treadmill-based aerobic exercise on functional capacity, pulmonary function, and clinical outcomes in children with asthma. Participants aged 10-17 years with physician-diagnosed asthma will be randomly assigned to either a virtual reality-based exercise group or a treadmill exercise group. Both groups will undergo supervised exercise training sessions twice a week for 8 weeks. Primary outcome will be the 6-Minute Walk Test. Secondary outcomes include pulmonary function, respiratory muscle strength, asthma control, quality of life, and exercise adherence.",[29],[289,94,290,291,292,293],"Virtual Reality","Aerobic Exercise","Pediatric Pulmonology","Exercise Training","Treadmill","2026-05-22",{"date":217,"type":34},{"date":297,"type":23},"2026-05-25",{"date":299,"type":23},"2027-05-10",{"name":301,"class":103},"Bezmialem Vakif University",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":310,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":313,"conditions":314,"keywords":316,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":74},"100640617","quantitative-chest-ct-and-multi-omics-to-distinguish-asthma-from-copd-and-predict-treatment-response-100640617","NCT07602192","Quantitative Chest CT and Multi-Omics to Distinguish Asthma From COPD and Predict Treatment Response","Prospective Multicenter Cohort to Discriminate Asthma Versus Chronic Obstructive Pulmonary Disease and Predict Treatment Response Using Quantitative Chest CT and Multi-Omics","CTOMICS","Inclusion Criteria:\n\n* Age ≥19 years\n* COPD group: post-bronchodilator FEV1\u002FFVC \\\u003C 0.70\n* Asthma group: clinically confirmed diagnosis of asthma by a physician\n* Able to provide voluntary written informed consent\n\nExclusion Criteria:\n\n* Acute exacerbation or active lower respiratory tract infection (e.g., pneumonia) within the past 4 weeks\n* Pregnancy or breastfeeding\n* Inability to undergo chest CT (e.g., poor cooperation or severe medical condition)\n* Refusal to consent to study procedures","19 Years",{"count":312,"type":23},200,"This study aims to improve the diagnosis and treatment prediction of asthma and chronic obstructive pulmonary disease (COPD) by combining quantitative chest computed tomography (CT) imaging with multi-omics data.\n\nAdults with asthma or COPD will be enrolled and undergo routine clinical evaluations, pulmonary function tests, blood tests, and chest CT scans. Additional samples, such as sputum and microbiome specimens, may also be collected. No experimental drugs or devices will be administered as part of this study.\n\nResearchers will analyze CT imaging features together with clinical, laboratory, and biological data to better distinguish asthma from COPD and to identify factors that may predict treatment response. The findings are expected to contribute to more precise and personalized management of chronic airway diseases.",[29,315],"COPD (Chronic Obstructive Pulmonary Disease)",[317,318,94,319,320],"Quantitative chest CT","Airway disease","Chronic Obstructive Pulmonary Disease","Treatment response","2026-05-20",{"date":294,"type":34},{"date":324,"type":34},"2025-12-22",{"date":326,"type":23},"2027-12-22",{"name":328,"class":103},"Korea University Guro Hospital",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":24,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":74},"100605311","obstructive-sleep-apnoea-and-difficult-asthma-osada-100605311","NCT07160868","Obstructive Sleep Apnoea and Difficult Asthma (OSADA)","Open-label Randomized Controlled Trial Investigating the Relationship Between Obstructive Sleep Apnoea and Difficult Asthma","OSADA","Inclusion Criteria:\n\n* Patients must have a clinical diagnosis of asthma with supportive objective diagnostics including but not limited to, variable airflow obstruction, bronchial-hyper responsiveness and demonstrable eosinophilic inflammation via fractional exhaled nitric oxide or peripheral eosinophilia\n* Patients receiving step 4 or step 5 of 'The Global Initiative for Asthma' (GINA) treatment guidelines will be selected\n* Between the ages of 18 to 90 years of age\n\nExclusion Criteria:\n\n* Patients with previous sleep study investigations\n* Excessive daytime sleepiness; ESS \\>17\n* Previous diagnosis of a sleep disorder\n* Resting hypoxaemia or need for long-term oxygen therapy\n* Inability to provide informed consent","90 Years",{"count":339,"type":23},80,[116],"The OSADA (Obstructive Sleep Apnoea in Difficult Asthma) trial is an open-label, randomized control trial investigating the impact of diagnosing and treating obstructive sleep apnoea (OSA) on a asthma control in patients with difficult-to-control asthma.\n\nParticipants will undergo home-based sleep studies to assess for OSA and are then allocated to one of three arms: 1) Patients with OSA treated with CPAP (intervention group), 2) Patients with OSA not treated for OSA (control group) and 3) Patients without OSA (reference group).\n\nThe primary objective is to evaluate whether treating OSA improves asthma control, symptom burden, and quality of life compared to untreated OSA and to patients without OSA. Secondary outcomes include exacerbation rates, sleep quality, and healthcare utilization.\n\nThis trial aims to clarify the contribution of OSA to poor asthma control and the potential benefits of integrated sleep and respiratory care in this complex population.",[29,343,344],"OSA - Obstructive Sleep Apnea","CPAP Treatment",{"date":346,"type":34},"2026-05-26",{"date":348,"type":34},"2025-09-01",{"date":294,"type":23},{"name":351,"class":103},"St. James's Hospital, Ireland",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":24,"phases":361,"briefSummary":363,"conditions":364,"keywords":367,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":377,"leadSponsor":379,"locationsCount":74},"100640560","phase-1-anakinra-rescue-treatment-for-moderate-asthma-attacks-artma-100640560","NCT07600190","Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)","Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA) Pilot Study","ARTMA","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Age ≥18 years\n* A history of physician-diagnosed persistent asthma or symptoms consistent with persistent asthma based on national or international guidelines for diagnosis and management of asthma.\n* Current use of controller therapy such as inhaled corticosteroid (ICS) or ICS in combination with long-acting beta agonist (LABA)\n* Asthma exacerbation requiring systemic corticosteroid therapy in the past 12 months\n* Negative pregnancy test for females who are not s\u002Fp hysterectomy with oophorectomy or who have been amenorrheic for 12 months or more.\n* Asthma Impairment and Risk Questionnaire (AIRQ) Score \\>2\n\nExclusion Criteria:\n\n* Clinical contraindications:\n\n  1. Physician diagnosis of other chronic pulmonary disease including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema or congenital disorders of the lungs or airways.\n  2. History of undergoing bronchial thermoplasty.\n  3. Intubation for asthma in the last 12 months\n  4. History of malignancy except non-melanoma skin cancer within the last five years.\n  5. Any chronic medical condition considered by the PI as a contraindication to inclusion in the study including significant cardiovascular disease, diabetes, chronic renal disease, chronic thyroid disease, history of chronic or recurrent infections or immunodeficiency.\n  6. Mental illness or history of substance abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.\n  7. History of smoking: i. Smoking \\>1 time per week in the past year; ii. If ≥40 years old: Smoked ≥15 pack years; iii. If \\\u003C40 years old: Smoked ≥10 pack years; iv. Smoking equivalents of 1 pack cigarettes a day for 1 year: 1 cigar or pipe daily for 1 year; Hookah - 1 session per day for 1 year; E-cigarettes or vapes - 1 cartridge\u002Ftank\u002Fpod per day for 1 year; and active use of smoking\u002Fvaping marijuana, specified as once per week in the last year.\n  8. Allergy\u002Fsensitivity to study drugs or their formulations, including latex\n  9. Unwillingness to use reliable contraception if sexually active (IUD, birth control pills\u002Fpatch, condoms).\n  10. Current participation in an interventional trial in which study administration was administered within the past 60 days or within 5 half-lives of the drug (whichever is greater)\n* Pregnancy, plans to get pregnant or nursing a baby. Female volunteers will be asked to use effective birth control (stable regimen of hormonal contraceptive use for at least 6 months, intrauterine device placement, or tubal ligation for at least 6 months through at least one week after study completion) and will provide a urine sample to test for pregnancy on study days. If the test is positive or the participant has reason to believe she may be pregnant, she will be dismissed from the study. Women who have been amenorrheic for 12 months may participate. Male volunteers will be asked to use condoms for the duration of the study through at least one week after study completion.\n* Usage of the following medications:\n\n  1. Use of daily systemic corticosteroid therapy for asthma control\n  2. Use of any immunomodulatory therapy within the preceding 12 months, including biologics that are approved for asthma.\n  3. Currently receiving allergen immunotherapy\n  4. Use of any immunosuppressant therapy within the preceding 12 months will be reviewed by the study physician.\n* Laboratory: Participants who meet the following criteria will be excluded from study:\n\n  1. Positive QuantiFERON-tuberculosis (TB) gold assay. Cases of indeterminate QuantiFERON-TB test results will require a second specimen to be drawn.\n  2. Baseline absolute neutrophil count (ANC) \\\u003C1.0 x 109\u002FL for participants of African descent, \\\u003C1.5 x 109\u002FL for other participants\n* Allergy\u002Fsensitivity to study drugs or their formulations, including latex.\n* History of anaphylaxis requiring epinephrine treatment\n* Inability or unwillingness of a participant to give written informed consent.\n* Inability or unwillingness to self-administer injectable medication (anakinra or placebo).",{"count":236,"type":23},[362],"PHASE1","In this single center, interventional pilot study, 40 participants at high risk for future exacerbation will be randomized to anakinra (v. placebo control) treatment for home administration as part of an asthma action plan (AAP) and monitored through their first moderate asthma exacerbation, triggering treatment dosing over a 26 week period. Key feasibility questions will be assessed in this pilot study to inform trial design and sample size selection for a future multi-site phase II clinical trial testing anakinra as a rescue treatment for moderate asthma exacerbations.",[29,365,366],"Persistent Asthma","Moderate Asthma Exacerbation",[94,368,369,370,371,372,373,365],"Asthma Exacerbation","Anakinra","Kineret","Interleukin-1 Receptor Antagonist","IL-1 receptor blockade","Airway Inflammation","2026-05-14",{"date":321,"type":34},{"date":219,"type":23},{"date":378,"type":23},"2028-12-01",{"name":380,"class":103},"University of North Carolina, Chapel Hill",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":74},"100612461","a-study-to-understand-the-accuracy-of-a-new-breathing-device-compared-to-standard-testing-for-asthma-and-copd-100612461","NCT07253883","A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD","A Diagnostic Accuracy Study: N-Tidal Assessment for Respiratory Diagnosis Compared to Using Standard Testing","STARDUST","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Referred for respiratory diagnostic testing with a clinical suspicion of asthma or COPD\n* Participant is willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Referred for respiratory diagnostic testing for a condition other than asthma or COPD, with no mention in the referral of a clinical suspicion of COPD or asthma\n* Participants who, in the opinion of the chief investigator, or their delegate, are unlikely to comply with the requirements of the study\n* Inability to give written informed consent\n* Participants who are acutely unwell\n* Patients unable to breathe through their mouths e.g. tracheostomy patients","110 Years",{"count":391,"type":23},1200,"The diagnosis of either asthma or chronic obstructive pulmonary disease (COPD) is currently based on a combination of symptoms, different lung tests and sometimes a 'trial by treatment'. Both COPD and Asthma tests currently include forced breathing using a test known as spirometry which can be difficult and uncomfortable for people to perform and needs expert interpretation. Asthma can require multiple tests in sequence which can make the process of diagnosis long and inconvenient for patients. In the UK, there have been challenges providing enough testing for COPD and asthma, in part because the tests are challenging to provide in the community to everyone who needs one.\n\nThe STARDUST study aims to test and develop new ways of diagnosing asthma and COPD that are quick, accurate and easy for patient and healthcare professionals to perform. People who have been referred for routine lung testing will breathe normally in and out into a handheld device called the N-Tidal Handset for 75 seconds. This device measures how the level of carbon dioxide (CO2) changes in the breath as people breath through it. The information gathered on the N-Tidal Handsets, called breath records or capnograms, will not be used to alter the diagnosis of any participants in the study.\n\nAfter the capnograms have been collected, the research team will test 'algorithms' that have been developed using artificial intelligence, to see if they can accurately identify the correct diagnosis. Information collected in the study will also be used to make improvements in these algorithms.\n\nIf confirmed to be accurate, these algorithms could be used in clinical practice to help healthcare professionals make faster, more accessible and accurate diagnoses, especially in settings like GP clinics in the community where access to specialist tests may be limited.",[29,315],[94,190,395,396,397],"End tidal CO2","Diagnostics","Machine learning","2026-04-21",{"date":400,"type":34},"2026-04-24",{"date":402,"type":23},"2026-04-01",{"date":404,"type":23},"2027-05-19",{"name":406,"class":103},"Liverpool Heart and Chest Hospital NHS Foundation Trust",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":24,"phases":416,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":74},"100633681","comparative-effects-of-alternative-nostril-breathing-versus-buteyko-breathing-on-control-pause-dyspnea-and-pulmonary-function-in-patients-with-bronchial-asthma-100633681","NCT07529847","Comparative Effects of Alternative Nostril Breathing Versus Buteyko Breathing on Control Pause, Dyspnea and Pulmonary Function in Patients With Bronchial Asthma","Inclusion Criteria:\n\n* Age between 18-45 years\n* Both genders (male and female)\n* Grade 1-3 on mMRC scale of dyspnea\n* Asthma severity classes- intermediate,mild persistent and moderate persistent asthma (acc. to NAEPP National Asthma Education and Prevention Program guidlines 2020)\n\nExclusion Criteria:\n\n* Patients having acute exerbation of COPD\u002Fstatus asthmaticus\n* Patients diagnosed with acute infection\n* Patients unable to follow command and instructions\n* Asthma patients with \\>40sec control pause duration","45 Years",{"count":415,"type":23},46,[116],"Bronchial asthma is a chronic inflmmatory airway disease characterized by recurrent episodes of dyspnea, wheezing, and airflow limitation.\n\nDysfunctional breathing pattern and chronic hyperventilation",[29],[420,421,422,423,424,425],"Bronchial asthma","alternative nostril breathing","buteyko breathing","dyspnea","pulmonary function","asthma control","2026-04-07",{"date":428,"type":34},"2026-04-14",{"date":430,"type":34},"2026-02-28",{"date":432,"type":23},"2026-05-15",{"name":434,"class":103},"Foundation University Islamabad",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":24,"phases":445,"briefSummary":446,"conditions":447,"keywords":453,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":74},"100632804","somatic-health-screening-for-adults-in-outpatient-psychiatric-care-in-denmark-somascreen-100632804","NCT07518446","Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)","Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) - Study Protocol for a Quasi-experimental Controlled Intervention Study With a Matched Cohort","SomaScreen","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Referred to FACT or OPUS psychiatric outpatient clinics in the Capital Region of Denmark.\n* Starting a new outpatient treatment episode in FACT or OPUS.\n* Diagnosed with psychotic or affective disorders (ICD-10 F20-F39), including those with comorbid substance use disorders (F10-F19).\n\nExclusion Criteria:\n\n* Individuals younger than 18 years.\n* Patients in geriatric outpatient clinics.\n* Individuals not in the target diagnosis group (i.e., without psychotic or affective disorders, F20-F39).\n* Individuals who do not meet the inclusion criteria above.",{"count":444,"type":23},2800,[116],"People with severe mental illness have a substantially increased risk of undiagnosed and insufficiently treated somatic disease. Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) is a service-level intervention implemented in psychiatric outpatient clinics in the Capital Region of Denmark to improve the detection and follow-up of somatic disease among patients with psychotic and affective disorders.\n\nThis study evaluates whether integrating structured somatic screening into mental health services leads to improved identification and management of somatic disease compared with care as usual. Using a quasi-experimental controlled design with a matched cohort, outcomes among patients exposed to the SomaScreen intervention are compared with those of patients receiving usual care in comparable psychiatric outpatient clinics outside the Capital Region.",[448,449,29,158,450,451,452],"Atrial Fibrillation (AF)","Heart Failure","Diabetes","Cancer","Psychiatric Patients, Serious Medical Illness",[454,455,456,457,458,459],"Somatic screening","Early diagnosis","Continuity of patient care","Cohort studies","Mental disorders","Health status disparities",{"date":461,"type":34},"2026-04-08",{"date":463,"type":34},"2024-09-01",{"date":465,"type":23},"2028-10-30",{"name":467,"class":103},"Amager Hospital",{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":74},"100620337","body-composition-related-evaluation-of-airway-tone-and-hyper-reactivity-using-oscillometry-100620337","NCT07356310","Body Composition Related Evaluation of Airway Tone and Hyper-rEactivity Using Oscillometry","BREATH-OSC","Inclusion Criteria:\n\n* Willingness to perform breathing test\n* Must be able to speak and understand English\n* Referred for Methacholine Challenge Test\n\nExclusion Criteria:\n\n* Unable to provide consent or perform oscillometry test",{"count":476,"type":23},100,"This study will determine if airway resistance to airflow and pressure, measured by Oscillometry, is associated with abnormal findings on methacholine challenge testing and whether these findings are associated with body habitus,",[479,480,29,481],"Breathing","Lung Function Decreased","Obesity",{"date":483,"type":34},"2026-04-13",{"date":485,"type":34},"2026-02-17",{"date":487,"type":23},"2027-11-01",{"name":489,"class":103},"University of Rochester",{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":112,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":24,"phases":498,"briefSummary":499,"conditions":500,"keywords":502,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":516,"locationsCount":74},"100631976","can-astaxanthin-help-manage-asthma-in-polluted-areas-100631976","NCT07507682","Can Astaxanthin Help Manage Asthma in POlluted Areas?","Investigating Astaxanthin as a Novel Therapy for Asthma Management in Polluted Environments","Inclusion Criteria:\n\n* Adults 18+ y\n* Confirmed clinical diagnosis of mild-to-moderate asthma, defined as:\n\n  * A physician diagnosed asthma condition consistent with BTS\u002FNICE\u002FSIGN (2024)\n  * Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment\n  * No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks\n\n(those with suspected Asthma will be invited to a familiarisation and eligibility session where they will have clinical investigations to assess for asthma and thus be included or excluded)\n\n* Ability to demonstrate acceptable and repeatable spirometry in accordance with ATS\u002FERS standards\n* Willing to refrain from antioxidant and anti-inflammatory supplementation (e.g. Omega-3, turmeric, NSAID supplements) for the duration of the study\n* Not consuming high dietary ASTX sources (e.g., frequent salmonid or crustacean intake), assessed at screening\n* non-smoking and non-vaping\n* Able and willing to take daily study capsules and attend all required visits\n* Able and willing to complete home monitoring, including peak flow, air-quality monitoring, and questionnaires\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased neutrophilic inflammation, which can obscure the true effects of asthma-target interventions\n* Respiratory tract infection within the preceding 4 weeks\n* Pregnant or lactating individuals\n* Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases\n* Renal or gastrointestinal disorders that may affect astaxanthin absorption and metabolism\n* Known allergy or hypersensitivity to ASTX or any components of the study supplement\n* History of current evidence of alcohol or substance abuse\n* Participation in another interventional drug or supplement study within the preceding 3 months\n* Use of medicines with a narrow therapeutic index where supplement interactions may pose risk (e.g., ciclosporin\u002Ftacrolimus, warfarin), assessed by investigator\n* Other significant chronic respiratory disease (e.g., COPD, bronchiectasis)",{"count":7,"type":23},[116],"This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.",[29,373,501],"Airway Hyperresponsiveness",[503,504,505,506,507,508,509],"Astaxanthin","Mild-to-Moderate Asthma","Air Pollution","FeNO","Hypertonic Saline Challenge","Impulse Oscillometry","Thoracic Bioelectrical Impedance Spectroscopy","2026-03-27",{"date":512,"type":34},"2026-04-02",{"date":432,"type":23},{"date":515,"type":23},"2026-07-20",{"name":517,"class":103},"Middlesex University",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":112,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":527,"conditions":528,"keywords":531,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":543,"locationsCount":74},"100630896","immune-status-and-disease-control-of-inflammatory-airway-diseases-100630896","NCT07493629","Immune Status and Disease Control of Inflammatory Airway Diseases","Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases","ISDC-IAD","Inclusion Criteria\n\n1. Age ≥18 years (≥40 years for COPD patients).\n2. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.\n3. PRISm patients (post-BD FEV1\u002FFVC ≥70% and FEV1 \\\u003C80% predicted)\n4. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.\n5. Healthy controls: normal lung function, FeNO \\\u003C20 ppb, total IgE \\\u003C100 IU\u002FmL, no chronic disease, smoking \\\u003C10 pack-years, no immunosuppressant use within 3 months.\n\nExclusion Criteria\n\n1. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.\n2. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.\n3. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)\n4. Pregnant or lactating women.\n5. Patients with poor compliance as judged by the investigators.\n6. Subjects currently participating in other clinical studies.",{"count":312,"type":23},"The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:\n\n1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.\n\nParticipants will:\n\n1. Answer questions about their health and symptoms.\n2. Give blood samples\n3. Have lung function tests and other standard check-ups.\n4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.",[373,158,29,160,529,530],"OSAS (Obstructive Sleep Apneas Syndrome)","Allergic Bronchopulmonary Aspergillosis (ABPA)",[532,533,534,535,536],"Airway Inflammatory Diseases","Immunophenotyping","Metabolomics","Cytometry by Time-of-Flight","High-dimensional immune profiling","2026-03-23",{"date":539,"type":34},"2026-03-25",{"date":541,"type":34},"2025-08-01",{"date":98,"type":23},{"name":544,"class":545},"First Affiliated Hospital of Ningbo University","NETWORK",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":18,"minAge":553,"maxAge":282,"enrollmentInfo":554,"targetDuration":4,"studyType":24,"phases":555,"briefSummary":556,"conditions":557,"keywords":560,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":74},"100627821","effect-of-aiartificial-intelligence-based-storytelling-video-on-anxiety-and-fear-during-skin-prick-test-in-children-100627821","NCT07453615","Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children","AI-Based Video-Mediated Cognitive Preparation in Skin Prick Testing: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged between 4 and 10 years (from 4th birthday to 11th birthday).\n* Children undergoing a Skin Prick Test (SPT) for the first time.\n* Presence of suspected Allergic Rhinitis and\u002For Asthma.\n* Cognitive ability to understand Turkish, follow the video story, and interpret visual assessment scales.\n* Parents with internet access to view the digital content.\n* Obtained parental informed consent and child assent (for ages 7 and above)\n\nExclusion Criteria:\n\n* Previous experience with Skin Prick Testing or a history of frequent medical procedures (e.g., frequent blood draws, surgeries) due to chronic illness.\n* Diagnosed with Autism Spectrum Disorder, severe ADHD(attention deficit hyperactivity disorder), intellectual disability, or severe psychiatric conditions preventing cooperation.\n* Significant visual or hearing impairments that prevent engagement with the video content.\n* Use of anxiolytics, sedatives, or medications affecting cognitive functions within the last 24 hours.\n* Chronic health problems (e.g., malignancy, immunodeficiency) that may elevate baseline anxiety levels.\n* Patients undergoing SPT for suspected Food Allergy, Drug Allergy, or Bee Venom Allergy.\n* For the intervention group: Failure to watch the video or answering the three \"validation questions\" incorrectly on the procedure day.","4 Years",{"count":476,"type":23},[116],"This study evaluates the effectiveness of an AI-generated therapeutic storytelling video on pre-procedural anxiety and fear levels in children aged 4 to 10 years undergoing their first Skin Prick Test (SPT). The study aims to determine if watching a cognitive preparation video at home prior to the appointment reduces anxiety compared to standard care. Participants will be randomized into two groups: an intervention group watching the AI-generated video and a control group receiving standard clinic care",[558,559,89,29],"Anxiety","Fear Anxiety",[561,128,562,563],"Skin Prick Test","Cognitive Preparation","Storytelling","2026-03-16",{"date":566,"type":34},"2026-03-18",{"date":568,"type":34},"2026-03-15",{"date":570,"type":23},"2026-09-15",{"name":572,"class":573},"Antalya Training and Research Hospital","OTHER_GOV",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":581,"targetDuration":4,"studyType":24,"phases":583,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":592,"locationsCount":74},"100629895","efficacy-of-indonesian-asthmatic-gymnastic-as-combine-pulmonary-rehabilitation-based-on-asthma-classification-100629895","NCT07480616","Efficacy of Indonesian Asthmatic Gymnastic as Combine Pulmonary Rehabilitation Based on Asthma Classification","EFFICACY OF INDONESIAN ASTHMATIC GYMNASTIC AS COMBINE PULMONARY REHABILITATION IN ASTHMATIC PATIENT BASED ON ASTHMA CLASSIFICATION","Inclusion Criteria:\n\n* Diagnosed with stable asthma\n* Age 18-65 years old\n* Competent and willing to be included in the trial\n\nExclusion Criteria:\n\n* Asthma exacerbation\n* Had other lung disease\n* Had neuromuscular disease affecting respiratory system",{"count":582,"type":23},35,[116],"This study aims to evaluate the efficacy of Indonesian Asthma Gymnastic for stable asthmatic patients in all asthma classification. The outcome measurements includes 6 minutes walk test, Asthma Control Test, peak flow rate value, and lung function. All participants have been in routine standard treatment of asthma (medication, education of healthy life style and smoking cessation).",[29,586],"Adult","2026-03-13",{"date":566,"type":34},{"date":590,"type":34},"2025-10-06",{"date":141,"type":23},{"name":593,"class":103},"RSUP Persahabatan",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":112,"sex":18,"minAge":601,"maxAge":602,"enrollmentInfo":603,"targetDuration":605,"studyType":155,"phases":4,"briefSummary":606,"conditions":607,"keywords":609,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":74},"100629289","investigation-and-classification-of-treatable-traits-in-patients-with-chronic-airway-diseases-100629289","NCT07472738","Investigation and Classification of Treatable Traits in Patients With Chronic Airway Diseases","An Observational Study for the Investigation and Classification of Treatable Traits in Patients With Chronic Airway Diseases","Inclusion Criteria:\n\n* Inclusion Criteria for Chronic Airway Disease Patients:\n\n  1. Age 20-75 years.\n  2. Meets the diagnostic criteria for COPD according to the 2022 GOLD guidelines OR meets the diagnostic criteria for asthma according to the 2022 GINA guidelines.\n  3. Willing and able to provide informed consent.\n* Inclusion Criteria for Healthy Controls:\n\n  1. Age ≥20 years.\n  2. No history of asthma symptoms or diagnosis of chronic respiratory diseases such as asthma or COPD.\n  3. Willing and able to provide informed consent and comply with the study protocol.\n\nExclusion Criteria:\n\n* (applies to all participants):\n\n  1. Respiratory tract infection, COPD acute exacerbation, or asthma acute exacerbation within the past 3 months.\n  2. Presence of other diseases causing significant lung tissue destruction, such as severe bronchiectasis or tuberculosis.\n  3. History of thoracic or abdominal surgery within the past 3 months.\n  4. Heart rate \\>120 beats per minute.\n  5. Ongoing anti-tuberculosis treatment.\n  6. Presence of other severe, uncontrolled systemic diseases.\n  7. Pregnant or lactating women.","20 Years","75 Years",{"count":604,"type":23},950,"1 Year","This research study focuses on chronic airway diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. These conditions make it difficult for patients to breathe, but breathing difficulty (dyspnea) is often perceived very differently. Some patients may feel severe distress with mild breathing problems, while others might not notice significant breathing issues even when lung function is poor. This difference in perception is termed \"dyspnea perception.\"\n\nThe main goal of this study is to understand how dyspnea perception varies among patients with chronic airway diseases. The investigators aim to determine if patients can be grouped into different subtypes based on the perception of breathing difficulties. The study will also investigate how these subtypes relate to other treatable characteristics, such as blood cell counts, allergy test results, and findings from lung function tests and brain scans.\n\nApproximately 800 patients with COPD or asthma and 150 healthy volunteers will participate. Participants will answer questionnaires, undergo lung function tests, provide blood samples, and a subset will undergo a special brain scan (functional MRI). No new treatments will be assigned; instead, these characteristics will be observed and measured over time.\n\nIt is hoped that this study will help doctors better understand chronic airway diseases and lead to more personalized management strategies for patients in the future.",[29,158,608],"Chronic Airway Diseases",[610,611,612,613,614],"Treatable Traits","Dyspnea Perception","Clinical Phenotyping","Observational Study","Functional Magnetic Resonance Imaging (fMRI)","2026-03-12",{"date":564,"type":34},{"date":618,"type":34},"2025-05-07",{"date":620,"type":23},"2027-12",{"name":622,"class":103},"Beijing Chao Yang Hospital",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":18,"minAge":184,"maxAge":234,"enrollmentInfo":631,"targetDuration":4,"studyType":24,"phases":633,"briefSummary":634,"conditions":635,"keywords":636,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":647,"leadSponsor":649,"locationsCount":74},"100627958","phase-2-pediatric-asthma-trial-of-corticosteroid-heterogeneity-patch-trial-of-dexamethasone-versus-methylprednisolone-for-pediatric-critical-asthma-100627958","NCT07455396","Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma","Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): A Phase 2 Prospective Randomized Open Blinded End-point (PROBE) Design, Randomized Clinical Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma","PATCH","Inclusion Criteria:\n\n* Age 3-17 years\n* Intensive care unit admission\n* Treatment for critical asthma\n\nExclusion Criteria:\n\n* History of unrepaired critical congenital heart disease\n* History of cystic fibrosis\n* Active tracheostomy dependence",{"count":632,"type":23},159,[26],"Acute asthma exacerbation is caused by dysregulated pulmonary inflammatory pathways such that standard treatment includes prompt administration of exogenous systemic corticosteroids (SCs), but there remains an ongoing dialogue among the expert medical community regarding the superiority of specific SCs including dose, frequency of administration, route, and delivery. Regimens are often chosen based on provider preference, and different strategies include once-daily dosing (ODD) dexamethasone (DM) 0.6 mg\u002Fkg\u002Fdose for 2 days, every 6 hours (q6h) DM 0.25 mg\u002Fkg\u002Fdose for 2 days, and methylprednisolone (MP) 1 mg\u002Fkg\u002Fdose every 6 hours for 5-days.\n\nTo address this knowledge gap, the investigators plan to perform a single-center, phase 2, randomized clinical trial of children 3-17 years of age hospitalized for critical asthma (CA) randomized to one of three regimens above. The study would be powered to evaluate rates of additional prescriptions of SC and also secondarily evaluate quality of life metrics.",[29],[637,638,639,640,641,642],"pediatric critical asthma","pediatric intensive care unit","status asthmaticus","systemic corticosteroids","methylprednisolone","dexamethasone","2026-03-03",{"date":645,"type":34},"2026-03-06",{"date":432,"type":23},{"date":648,"type":23},"2028-05-14",{"name":650,"class":103},"Johns Hopkins All Children's Hospital",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":657,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":659,"targetDuration":4,"studyType":24,"phases":661,"briefSummary":662,"conditions":663,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":42},"100625321","multicomponent-breathlessness-and-physical-activity-intervention-in-people-with-asthma-using-a-digital-platform-100625321","NCT07421115","Multicomponent Breathlessness and Physical Activity Intervention in People With Asthma Using a Digital Platform","Multicomponent Breathlessness and Physical Activity Intervention in People With Moderate to Severe Asthma Using a Supported Digital Platform","BRAID","Inclusion Criteria:\n\n* Aged 18 years or older\n* Able to provide informed consent\n* Evidence of variable airflow limitation within the past 10-years to confirm asthma diagnosis\n* Meets diagnostic criteria for moderate, or severe asthma\n* Reports breathlessness impacting daily life physical activities (modified Medical Research Council \\[mMRC\\] dyspnoea score ≥1) within the past 1-week\n* Owns a smart device with internet access, which they are willing and able to use for the study duration\n\nExclusion Criteria:\n\n* High dependence on medical care\n* Significant life-limiting comorbidity (\\\u003C12 months life expectancy)\n* Cognitive impairment, poor English language skills or significant untreated hearing impairment that prevents completion of data collection forms or understanding of verbal instructions\n* Current participation in any other clinical trial, or participation in another clinical trial within the 4-weeks preceding study entry.",{"count":660,"type":23},300,[116],"Treating breathlessness could help people with asthma have fewer symptoms and be more physically active. People with asthma report that it is important to deal with breathlessness during physical activity programs, but past research hasn't focused on this need.\n\nThe investigators have developed a multicomponent digitally supported intervention targeting breathlessness and physical inactivity. This study will test whether the multicomponent digital supported intervention will help people with asthma. The main question the study aims to answer is:\n\nDoes the multicomponent digitally supported intervention improve quality of life?\n\nParticipants will:\n\n* Be allocated to the intervention or usual care. Allocation to either group will be random (like tossing a coin).\n* Attend study visits to complete an assessment involving questionnaires and measurements\n* Receive telephone calls to ask questions about health\n* Be invited to take part in an interview to have a conversation about thoughts on participating in the study\n* Be asked to provide consent to collect information from Services Australia regarding use of health care services and medications",[29,163],"2026-02-16",{"date":666,"type":34},"2026-02-19",{"date":668,"type":23},"2026-03-01",{"date":670,"type":23},"2028-10-01",{"name":672,"class":103},"University of Newcastle, Australia",{"id":674,"slug":675,"hasResults":12,"nctId":676,"briefTitle":677,"officialTitle":677,"acronym":4,"eligibilityCriteria":678,"healthyVolunteers":12,"sex":18,"minAge":679,"maxAge":19,"enrollmentInfo":680,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":682,"conditions":683,"keywords":685,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":688,"lastUpdatePostDateStruct":689,"startDateStruct":690,"completionDateStruct":691,"leadSponsor":692,"locationsCount":4},"100624629","research-on-disease-control-and-mental-health-status-of-adolescent-asthma-patients-100624629","NCT07412119","Research on Disease Control and Mental Health Status of Adolescent Asthma Patients","Inclusion Criteria:\n\n* Meet the asthma diagnostic criteria of GINA 2025\n* Age 12 to 18 years old\n* The parents and the child patient agreed and filled out the questionnaire completely.\n\nExclusion Criteria:\n\n* Children with other respiratory diseases such as bronchiectasis, bronchiolitis, cystic fibrosis and pneumonia\n* Combined with chronic diseases of other systems","12 Years",{"count":681,"type":23},460,"Background: Currently in China, adolescent asthma care is characterized by both undertreatment and overtreatment. Patients in this age group may exhibit negative emotions toward disease treatment and long-term control. Insufficient disease knowledge, irregular lifestyle habits, and negative attitudes toward the disease can all reduce medication adherence, affect disease control outcomes, and thereby increase the risk of severe chronic respiratory conditions and disease burden in adulthood.\n\nObjectives: To assess disease control status in adolescent asthma patients, evaluate the psychological well-being of patients and their family members, and understand patients' self-management skills and readiness for transition to adulthood.\n\nProcedures: Eligible participants will complete a series of assessment questionnaires through the Youran Huxi mobile application, including questionnaires on asthma control, physical activity, psychological health, self-management behaviors, and transition readiness. The study period is 12 months; the baseline assessment involves one-time completion of written questionnaires with no interim follow-up visits. The study does not intervene in clinical diagnosis or treatment decisions.",[29,684],"Adolescent - Emotional Problem",[94,686,687],"adolescent","mental health","2026-02-12",{"date":485,"type":34},{"date":402,"type":23},{"date":100,"type":23},{"name":693,"class":103},"Beijing Children's Hospital"]